- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03242954
Innovative Approaches for Minor Consent: Consent 2.0
Innovative Approaches for Minor Consent: Consent 2.0 - A Multi-Center Study of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Potential participants will be recruited from clinical settings and HIV testing centers. If interested in participation, they will take a short Computer Assisted Self-Interview (CASI) screening survey to determine eligibility. Those eligible will take part in the one-day study visit at that time or will provide contact information to set up the study visit at a later date.
All study participants will attend a one-day study visit at their respective study site. Upon arrival, participants will complete a CASI that collects demographic, social, behavioral, and attitudinal measures. Next, participants will take part in a simulated consent process for two hypothetical trials modeled after ATN 113 and HPTN 077. Study procedures differ for adolescents and parents, so each group is described separately below:
Adolescent Participants: For each hypothetical trial, research staff will lead the participant through a simulated consent process consistent with their randomized consent condition. Then, the participant will complete a CASI assessing Willingness to Participate (WTP) and will work with research staff to complete the University of San Diego (UCSD) Brief Assessment of Capacity to Consent (UBACC).
Parent Participants: For each hypothetical trial, research staff will review the informed consent forms with the parent. The parent will complete a CASI with three vignettes that describe each of the three possible consent conditions. Parents will rate the acceptability of each vignette. Then, the participant will work with research staff to complete the UCSD Brief Assessment of Capacity to Consent (UBACC). Finally, the participant will answer a series of questions via CASI.
A subset of 6-8 adolescents and 6-8 parents per study site will complete a debriefing interview assessing adolescent and parent perspectives on the various consent conditions in greater depth, and to better understand the role of study features, family, and adolescent characteristics in willingness to participate/willingness to support the hypothetical research studies.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Children's Hospital Colorado/Univ of Colorado SOM
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33606
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins University/SOM
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Note: Age limits apply to adolescent participants and to the adolescent children of parent participants.
Adolescent Inclusion Criteria
- Age 14-17 inclusive
- Able to read and speak English
- HIV status is negative or unknown
- Engaged in high-risk sexual activity in the last six months
Adolescent Exclusion Criteria
- Child of a parent already enrolled in the study
Parent Inclusion Criteria
- Able to read and speak English
- Parent or guardian of an adolescent who is between ages 14-17
- The parent/guardian's adolescent's HIV status is either negative or unknown
Parent Exclusion Criteria
- Parent of a child already enrolled in the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Adolescents: Consent Condition 1
Autonomous minor consent
|
Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
|
Aktiv komparator: Adolescents: Consent Condition 2
Adult permission required
|
Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
|
Aktiv komparator: Adolescents: Consent Condition 3
Parental permission required
|
Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
|
Aktiv komparator: Parents: Consent Conditions 1-3
Autonomous minor consent, adult permission required, and parental permission required
|
Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Mean Adolescent WTP Scores
Tidsramme: Day 1
|
Comparing mean adolescent Willingness to Participate (WTP) scores across the three consent conditions and two trial types. WTP scores are based on the response to the question: "If offered the chance, how likely would you be to participate in the study?" Responses are collected using a Likert scale (definitely not participate, probably not participate, might or might not participate, probably participate, definitely participate) and converted to a numeric score with values ranging from 1 (definitely not participate) to 5 (definitely participate) for analysis. |
Day 1
|
Mean Parent WTS Scores
Tidsramme: Day 1
|
Comparing mean parent Willingness to Support (WTS) scores across the three consent conditions and two trial types. WTS scores are based on the response to the question: "This is an acceptable approach to consent for your teenager's participation in the study." Responses are collected using a Likert scale (strongly disagree, disagree, neither disagree nor agree, agree, strongly agree) and converted to a numeric score with values ranging from 1 (strongly disagree) to 5 (strongly agree) for analysis. |
Day 1
|
Effects of the Study Agent (Stage of Development and Method of Delivery) on High-risk Minor Adolescents' WTP Scores
Tidsramme: Day 1
|
This data reflects adolescent Willingness to Participate (WTP) scores by study agent/trial type.
After review of hypothetical consent documents for 2 study agents in different stages of development and with different methods of delivery (based on real-world studies ATN 113 and HPTN 077), adolescents are asked "If offered the chance, how likely would you be to participate in the study?"
Responses are collected using a Likert scale (definitely not participate, probably not participate, might or might not participate, probably participate, definitely participate) and converted to a numeric score with values ranging from 1 (definitely not participate) to 5 (definitely participate) for analysis.
|
Day 1
|
Effects of the Study Agent (Stage of Development and Method of Delivery) on Parents' Acceptability Scores
Tidsramme: Day 1
|
After review of hypothetical consent documents for 2 study agents in different stages of development and with different methods of delivery (based on real-world trials ATN 113 and HPTN 077), parents are presented with vignettes for the 3 different consent conditions (autonomous minor consent, adult permission required, parental permission required) and asked "How acceptable is this approach to research consent?".
Responses are collected on a Likert scale (completely unacceptable, unacceptable, neither unacceptable not acceptable, acceptable, completely acceptable) and converted to a numeric score with values ranging from 1 (definitely not acceptable) to 5 (definitely acceptable) for analysis.
|
Day 1
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Amy Knopf, PhD, MPH, RN, Indiana University School of Medicine
- Studieleder: Matthew Psioda, PhD, University of North Carolina, Chapel Hill
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 17-0538
- 5U24HD089880-02 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutteringHIV | HIV-testning | HIV-kobling til pleje | HIV behandlingForenede Stater
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationAfsluttetPartner HIV-testning | Par HIV Rådgivning | Parkommunikation | HIV-forekomstCameroun, Dominikanske republik, Georgien, Indien
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement og andre samarbejdspartnereUkendtHIV | HIV-uinficerede børn | Børn udsat for HIVCameroun
-
University of MinnesotaTrukket tilbageHIV-infektioner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS og infektionerForenede Stater
-
Hospital Clinic of BarcelonaAfsluttetIntegrasehæmmere, HIV; HIV PROTEASE HÆMMERSpanien
-
Erasmus Medical CenterIkke rekrutterer endnuHIV-infektioner | Hiv | HIV-1-infektion | HIV I infektionHolland
-
University of Maryland, BaltimoreTrukket tilbageHiv | Nyretransplantation | HIV reservoir | CCR5Forenede Stater
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London og andre samarbejdspartnereRekrutteringHIV | HIV-testning | Tilknytning til plejeSydafrika
-
National Taiwan UniversityRekruttering
-
Helios SaludViiV HealthcareUkendtHiv | HIV-1-infektionArgentina
Kliniske forsøg med Autonomous minor consent
-
University of PennsylvaniaAfsluttet
-
University of AarhusEurostarsUkendtIdiopatisk lungefibroseDanmark
-
National Yang Ming UniversityCheng-Hsin General HospitalAfsluttetSkuldersmerter | Scapular dyskinesis | SkulderpåvirkningTaiwan
-
SpirogenAfsluttetAkut myeloid leukæmi | Kronisk lymfatisk leukæmiForenede Stater
-
Istinye UniversityAfsluttetUndersøgelsen vil ikke være baseret på nogen sygdom | Evne til at svømme 100m selvstændig fri | Være mellem 9-16 år | Fortsætter med at løbe som en del af en sportsklubKalkun
-
Emory UniversityIkke rekrutterer endnuRotator Cuff Tear Arthropathy | Omvendt total skulderplastik | Avanceret Glenohumeral slidgigtForenede Stater
-
Yale UniversityAfsluttetPatientcentreret resultatforskningForenede Stater
-
Riphah International UniversityRekrutteringScapular dyskinesis | Pectoralis Minor SyndromPakistan
-
DERSHENG SUNUkendt
-
DuomedAfsluttetPerifer arteriel sygdom | Iliac arterie sygdom | Femoropoliteal okklusiv sygdom | Obstruktion under knæetBelgien